Compare DexCom, Inc. (DXCM) vs iShares Core MSCI EAFE ETF (IEFA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs iShares Core MSCI EAFE ETF — how do they compare? DexCom, Inc. trades at $84.47 (market cap $31.86B), while iShares Core MSCI EAFE ETF trades at $96.14 (market cap $189.19B). The key difference: iShares Core MSCI EAFE ETF is far larger — about 5.9× DexCom, Inc.'s market cap, and DexCom, Inc. is trading nearer its 52-week high, iShares Core MSCI EAFE ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and iShares Core MSCI EAFE ETF for 41 Days on average.
| DXCM | IEFA | |
|---|---|---|
Market Cap | $31.86B | $189.19B |
Volume | 3,607,070 | 8,441,787 |
Sector | Health | Broad Market / Factor |
52-Week High | $92.34 | $101.41 |
52-Week Low | $54.84 | $85.06 |
Typical Hold Time | 62 Days | 41 Days |
Enterprise Value | $31.32B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $84.3, up 1.09% today, with a bearish technical signal despite strong fundamentals. The company reported Q2 2026 EPS of $0.70, beating estimates, continuing a trend of earnings outperformance. Revenue growth is robust, with 2025 revenue reaching $4.66 billion and net income margin improving to 20.12%. Analyst consensus is strongly bullish with an 80.77% buy rating and a $95.07 price target, suggesting significant upside from current levels.
The outlook for DXCM is positive driven by expansion in continuous glucose monitoring for Type 2 diabetes, as highlighted in recent company reports. Key risks include competitive pressures and reimbursement challenges. With solid cash flow generation and institutional support, the stock presents a growth opportunity, though investors should monitor execution against high expectations.
IEFA trades at $96.18, down 0.02% on the day, with a bearish technical outlook indicated by moving averages and oscillators. The ETF, managed by BlackRock, holds $196 billion in assets and focuses on developed markets outside North America. Recent news highlights comparisons with competing international ETFs, noting its higher dividend yield and lower expense ratio relative to some peers, though performance has lagged behind certain total-world and emerging market funds over the past year.
The outlook for IEFA is clouded by technical weakness and competitive pressures, though its scale and cost efficiency offer stability. Key risks include concentration in developed markets, which may underperform during global growth shifts, and the impact of geopolitical tensions on international equities. Analyst sentiment is mixed, with the fund's defensive characteristics balancing against limited near-term catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About iShares Core MSCI EAFE ETF
IEFA tracks the MSCI EAFE Investable Market Index, offering broad exposure to large, mid, and small-cap stocks in developed markets across Europe, Australasia, and the Far East. It serves as a low-cost core holding for international diversification, excluding the U.S. and Canada.
Read more on IEFA →
